NCT05954988View on ClinicalTrials.gov

A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

September 25, 2024

Study Completion Date

September 25, 2024

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

LTI-03

Caveolin-1-Scaffolding-Protein-Derived Peptide

DRUG

Placebo

Matching placebo

Trial Locations (7)

35294

University of Alabama, Birmingham

90033

University of Southern California, Los Angeles

90048

Cedars Sinai Medical Center, Los Angeles

Unknown

Agaplesion Evangelisches Krankenhaus Mittelhessen, Giessen

University of Edinburgh, Edinburgh

Royal Victoria Infirmary, Newcastle

SW3 6HP

Royal Brompton Hospital, London

Sponsors

Lead Sponsor

Rein Therapeutics
All Listed Sponsors
lead

Rein Therapeutics

INDUSTRY

NCT05954988 - A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients | Biotech Hunter | Biotech Hunter